85
Participants
Start Date
July 22, 2019
Primary Completion Date
November 13, 2023
Study Completion Date
November 13, 2023
RO7200220
RO7200220 was administered as IVT injection.
Ranibizumab
Ranibizumab was administered as IVT injection.
Mid Atlantic Retina, Philadelphia
Cumberland Valley Retina PC, Hagerstown
Univ of Virginia Ophthalmology, Charlottesville
Wake Forest Baptist Medical Center, Winston-Salem
Florida Eye Associates, Melbourne
Retina Vitreous Assoc of FL, St. Petersburg
Cleveland Clinic Foundation, Cleveland
Illinois Retina Associates SC, Oak Park
Medical Center Ophthalmology Associates, San Antonio
Valley Retina Institute P.A., McAllen
Austin Clinical Research LLC, Austin
Retina Res Institute of Texas, Abilene
Sierra Eye Associates, Reno
Retina-Vitreous Associates Medical Group, Beverly Hills
Retina Institute of California Medical Group d/b/a Acuity Eye Group, Palm Desert
California Retina Consultants, Oxnard
Byers Eye Insitute at Stanford, Palo Alto
Oregon HSU, Portland
Karalis Johnson Retina Center, Seattle
Hoffmann-La Roche
INDUSTRY